NNH

New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024

Retrieved on: 
Saturday, April 6, 2024
Mental Health, Research, Neurology, Clinical Trials, Biotechnology, Managed Care, Health, Pharmaceutical, Science, TEVA, De novo, Patient, Interview, NNH, Tardive dyskinesia, Congress, Medication, Risperidone, International, Risk, NNT, Caregiver, Safety, HCP, Emotion, Teva Pharmaceuticals, Health professional, Data wrangling, Death, Lais, Teva, FDA, Olanzapine, SIRS, Perception, Physician, Schizophrenia International Research Society, Persistence

The data were presented at the 2024 Congress of the Schizophrenia International Research Society (SIRS) taking place from April 3-7, 2024 in Florence, Italy.

Key Points: 
  • The data were presented at the 2024 Congress of the Schizophrenia International Research Society (SIRS) taking place from April 3-7, 2024 in Florence, Italy.
  • “Schizophrenia is a complex mental health condition where the treatment needs and preferences of those living with it may evolve over time.
  • In the patient survey, approximately 20 patients and 19 caregivers completed a 60-minute interview regarding the use of LAIs in schizophrenia.
  • Below is the full set of data presented by Teva at SIRS 2024.

Teva to Present New Data Supporting Safety, Efficacy and Real-World Effectiveness of AUSTEDO® (deutetrabenazine) Tablets at the 2023 HSG Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, FDA, VMAT2, NNH, NYSE, Georgetown University School of Medicine, Medication, HD, MD, NNT, Psychiatry, START, Doctor of Philosophy, PGIC, TEVA, Yahoo Beijing Global R&D Center, Teva, Tetrabenazine, Interim, Annual general meeting, Teva Pharmaceuticals, TASE, TMC, Education, Safety, HSG, Patient, Pharmaceutical industry

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new HD data will be presented at the Huntington Study Group® (HSG) Annual Meeting on November 2-4 in Phoenix, AZ.

Key Points: 
  • Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new HD data will be presented at the Huntington Study Group® (HSG) Annual Meeting on November 2-4 in Phoenix, AZ.
  • TMC scores mostly improved with AUSTEDO treatment, and the safety profile was consistent with AUSTEDO’s known safety profile.
  • NNTs for treatment success based on CGIC and PGIC ranged from 3-4 and 4-5, respectively, for the VMAT2 inhibitors.
  • Significant NNHs included:
    Together, the data provide additional insight into the real-world efficacy and safety of AUSTEDO for patients with HD chorea.

Scilex Holding Company Presented Oral and Poster Presentations on Elyxyb at the 2023 Annual Brain Week Conference Held in Las Vegas, NV

Retrieved on: 
Tuesday, September 12, 2023
NNT, New England Institute of Religious Research, PALO, Acute, CGRP, Headache, NNH, MD, Patient, Rimegepant, Post hoc analysis, Hour, OTC, Neurology, Ubrogepant, Therapy, Calcitonin gene-related peptide, Chronic pain, Conference, Pharmaceutical industry, Migraine

PALO ALTO, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that it presented oral and poster presentations at the 2023 Annual Brain Week Conference on the benefits of Elyxyb (celecoxib oral solution).

Key Points: 
  • PALO ALTO, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that it presented oral and poster presentations at the 2023 Annual Brain Week Conference on the benefits of Elyxyb (celecoxib oral solution).
  • The conference was held from September 6-8, 2023 in Las Vegas, NV.
  • Taken together, these data suggest that to achieve pain freedom with Elyxyb, fewer patients need to be treated and may have less likelihood of being harmed, than with ubrogepant or rimegepant.
  • Elyxyb is a remarkable addition to armamentarium for treatment of acute migraine.” said Stewart Tepper, MD, The New England Institute for Neurology and Headache, Stamford, CT, USA.